PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 252
- Registration Number
- NCT06977581
- Locations
- 🇺🇸
Velocity Clinical Research, Mobile, Mobile, Alabama, United States
🇺🇸Clinical Research of Rock Hill, Rock Hill, South Carolina, United States
🇺🇸Allergy and Asthma Associates of Santa Clara Valley Research Center, San Jose, California, United States
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
Phase 1
Not yet recruiting
- Conditions
- Carcinoma, Non Small Cell LungSquamous Cell Carcinoma of the Head and Neck (SCCHN)Carcinoma, Pancreatic DuctalMalignant Melanoma
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 399
- Registration Number
- NCT06974734
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults
Phase 1
Not yet recruiting
- Conditions
- Healthy
- Interventions
- Biological: PF-07999415Drug: Placebo
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT06965465
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Phase 1
Not yet recruiting
- Conditions
- Breast CancerBreast Neoplasms
- Interventions
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT06966453
A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1000
- Registration Number
- NCT06962969
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-postive Metastatic Breast Cancer.
Not yet recruiting
- Conditions
- Metastatic HER2+ Advanced Breast Cancer
- Interventions
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06961331
A Study to Learn More About TIVDAK in Women With Cervical Cancer That Has Come Back
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT06952660
A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19
Active, not recruiting
- Conditions
- COVID-19 SARS-CoV-2 InfectionCOVID-19COVID-19 InfectionCoronavirus Disease 2019 (COVID-19)COVID-19 (Coronavirus Disease 2019)COVID-19 VaccinationCOVID-19 VaccinesSARS-CoV-2 Infection, COVID19SARS-CoV-2 Infection, COVID-19
- Interventions
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06923137
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults.
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT06920498
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity
Phase 1
Active, not recruiting
- Conditions
- OverweightObesity
- Interventions
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT06910839
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
© Copyright 2025. All Rights Reserved by MedPath